{"id":"symtuza-taf-ftc-drv-c","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Rash"},{"rate":null,"effect":"Elevated lipids"},{"rate":null,"effect":"Renal function changes"}]},"_chembl":{"chemblId":"CHEMBL262331","moleculeType":"Small molecule","molecularWeight":"476.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combination contains tenofovir alafenamide (TAF) and emtricitabine (FTC), which are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, plus darunavir (DRV), a protease inhibitor that prevents HIV protease from cleaving viral polyproteins. Cobicistat (c) is a pharmacokinetic booster that inhibits CYP3A4 to increase darunavir exposure.","oneSentence":"Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:25.832Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT03685500","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2018-12-04","conditions":"HIV Infections","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Symtuza® (TAF/FTC/DRV/c)","genericName":"Symtuza® (TAF/FTC/DRV/c)","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}